As of 2026-03-25, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -19.80 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 5.86 CAD, the upside of Briacell Therapeutics Corp is -437.85%.
Based on its market price of 5.86 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 437.85%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -19.80 - -19.80 | -19.80 | -437.85% |
| P/E | (25.50) - (15.68) | (22.47) | -483.5% |
| DDM - Stable | (35.23) - (96.76) | (65.99) | -1226.2% |
| DDM - Multi | (28.95) - (62.17) | (39.54) | -774.8% |
| Market Cap (mil) | 42.49 |
| Beta | -1.13 |
| Outstanding shares (mil) | 7.25 |
| Enterprise Value (mil) | 39.77 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.78% |
| Cost of Debt | 5.00% |
| WACC | 6.73% |